申请人:Akzo Nobel N.V.
公开号:US05470856A1
公开(公告)日:1995-11-28
The invention is concerned with a tetrahydropyrimidine derivative having formula I ##STR1## wherein R.sub.1 is hydrogen; R.sub.2 is hydrogen, a lower alkyl group, or lower acyl; or R.sub.1 and R.sub.2 represent together a bond; R.sub.3 is hydrogen, a lower hydrocarbon group optionally substituted with halogen, CN, aryl, or COR.sub.7 ; R.sub.4 is hydrogen, a lower alk(en)yl group, or aryl; R.sub.5 is hydrogen, amino, lower alkyl substituted amino, or a lower alkyl group; and R.sub.6 is hydrogen or methyl; R.sub.7 is amino, lower alkyl substituted amino, or a lower alkyl group; or a pharmaceutically acceptable salt thereof. The compounds of this invention have muscarinic properties and can be used for the treatment of cognition disorders, and for the treatment of cholinergic deficiencies.
该发明涉及一种具有式I的四氢嘧啶衍生物##STR1##
其中,R.sub.1为氢;R.sub.2为氢、较低的烷基或较低的酰基;或R.sub.1和R.sub.2共同表示键;R.sub.3为氢、较低的烃基,可选地被卤素、CN、芳基或COR.sub.7取代;R.sub.4为氢、较低的烷基或芳基;R.sub.5为氢、氨基、较低烷基取代氨基或较低的烷基;R.sub.6为氢或甲基;R.sub.7为氨基、较低烷基取代氨基或较低的烷基;或其药学上可接受的盐。本发明化合物具有毒蕈碱性质,可用于治疗认知障碍和胆碱能缺乏症的治疗。